elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q55605012-1CFA290B-E68F-4524-B96D-E9702C7A1AAE
Q55605012-1CFA290B-E68F-4524-B96D-E9702C7A1AAE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55605012-1CFA290B-E68F-4524-B96D-E9702C7A1AAE
Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.
P2860
Q55605012-1CFA290B-E68F-4524-B96D-E9702C7A1AAE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55605012-1CFA290B-E68F-4524-B96D-E9702C7A1AAE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d203ea5eed64ef282ba1b315c916d14168af5738
P2860
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection